​

Roivant Sciences Stock (NASDAQ:ROIV)

ForecastRevenueOwnershipFinancialsChartTranscripts
Roivant Sciences by TradingView

Previous Close

$11.55

52W Range

$8.73 - $13.05

50D Avg

$11.22

200D Avg

$11.18

Market Cap

$7.72B

Avg Vol (3M)

$6.05M

Beta

1.15

Div Yield

-

ROIV Company Profile

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

GB

Employees

908

IPO Date

Dec 08, 2020

Website

ROIV Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceMar 24Mar 23
Product$75.06M$28.01M

Fiscal year ends in Mar 24 | Currency in USD

ROIV Financial Summary

Mar 24Mar 23
Revenue$124.80M$61.28M
Operating Income$4.24B$-1.18B
Net Income$4.35B$-1.01B
EBITDA$-996.51M$-1.18B
Basic EPS$5.55$-1.42
Diluted EPS$5.23$-1.42

Fiscal year ends in Mar 24 | Currency in USD

Latest Earnings Call Transcripts

Q4 24May 29, 25 | 8:00 AM
Q3 24Feb 10, 25 | 8:00 AM
Q2 24Nov 12, 24 | 8:00 AM

Peer Comparison

TickerCompany
RLAYRelay Therapeutics, Inc.
ABUSArbutus Biopharma Corporation
ARQTArcutis Biotherapeutics, Inc.
LEGNLegend Biotech Corporation
PROKProKidney Corp.
PTGXProtagonist Therapeutics, Inc.
IMVTImmunovant, Inc.